Vermillion Wealth Management’s Haemonetics HAE Stock Holding History

Vermillion Wealth Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$113	–	1921
2026 Q1	$113	Buy	+2	New	+$130	﹤0.01%	1420

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vermillion Wealth Management's HAE Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 2 shares — an estimated $113 sold.

Vermillion Wealth Management first reported a position in HAE in Q1 2026 and held it in 1 quarter. The position peaked at $113 in Q1 2026. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Vermillion Wealth Management reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
Vermillion Wealth Management sold 2 Haemonetics shares in Q2 2026, an estimated $113.
Vermillion Wealth Management first reported a position in Haemonetics in Q1 2026 and held it in 1 quarter.
Vermillion Wealth Management's Haemonetics position peaked at $113 in Q1 2026.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.